



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 4225

<b>SERIAL NUMBER</b> 10/524,081	<b>FILING OR 371(c) DATE</b> 02/24/2006 <b>RULE</b>	<b>CLASS</b> 514	<b>GROUP ART UNIT</b> 1626	<b>ATTORNEY DOCKET NO.</b> RLL -260US
------------------------------------	---	---------------------	-------------------------------	--

**APPLICANTS**  
 Anita Mehta, Plainfield, IL;  
 Arundutt V.Silamkoti, Secunderabad, INDIA;  
 Miriyala Bruhaspathy, Andhra Pradesh, INDIA;  
 Jang Bahadur Gupta, Dusseldorf, GERMANY;

**\*\* CONTINUING DATA \*\*\*\*\***  
 This application is a 371 of PCT/IB02/03167 08/09/2002 **JN**

**\*\* FOREIGN APPLICATIONS \*\*\*\*\***

**IF REQUIRED, FOREIGN FILING LICENSE GRANTED \*\***  
 08/23/2006

Foreign Priority claimed 35 USC 119 (a-d) conditions met Verified and Acknowledged	<input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance Examiner's Signature <i>[Signature]</i> Initials <b>JN</b>	<b>STATE OR COUNTRY</b> IL	<b>SHEETS DRAWING</b> 0	<b>TOTAL CLAIMS</b> 12	<b>INDEPENDENT CLAIMS</b> 4
--	---	-------------------------------	----------------------------	---------------------------	--------------------------------

**ADDRESS**  
26815

**TITLE**  
3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists

<b>FILING FEE RECEIVED</b> 1590	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees ( Filing )
		<input type="checkbox"/> 1.17 Fees ( Processing Ext. of time )
		<input type="checkbox"/> 1.18 Fees ( Issue )
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit